Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations

Bal, Suzanne M.; Slütter, Bram; Riet, Elly van; Kruithof, Annelieke C.; Ding, Zhi; Kersten, Gideon; Jiskoot, Wim; Bouwstra, Joke A.

doi:10.1016/j.jconrel.2009.11.018

Cited by 82 publications

(44 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twelve TMC nanoparticles carried a positive zeta potential of 14.6˘0.8 mV at physiological pH ( Figure 4B). TEM images ( Figure 5A) indicate that the nanoparticles were spherical in shape, with no obvious particle aggregation; this was further confirmed by AFM (Figure 5B), and is not consistent with the previous finding that nanoparticles loaded with antigen have an irregular shape [13]. All antibiotic-loaded formulations showed good loading efficiency (73.65%˘1.83%), while the extent of drug loading, expressed as mass of VCM per mass of nanoparticles, was much lower (5.80%˘0.17%).…”

Section: Characterization Of Vcm/tmc Nanoparticlescontrasting

confidence: 50%

Preparation and Evaluation of Vancomycin-Loaded N-trimethyl Chitosan Nanoparticles

Shou³

et al. 2015

Polymers

View full text Add to dashboard Cite

Chronic intracellular infections caused by drug-resistant pathogens pose a challenge to the treatment of chronic osteomyelitis. Such treatment requires an intracellular delivery system for the sustained release of antibiotics such as vancomycin (VCM), which is an antibiotic of last resort used against many clinically resistant bacteria. In this work, we report VCM-loaded N-trimethyl chitosan (TMC) nanoparticles and their potential application for drug delivery. The results showed that the prepared nanoparticles were predominantly spherical in shape with an average particle diameter of 220 nm, a positive zeta potential, and a loading efficiency of 73.65%˘1.83%. Furthermore, their drug release profile followed the Higuchi model for sustained release, with non-Fickian diffusion. Over a 24-h period, 6.51%˘0.58% of the drug within the optimized nanoparticles was released. In vitro cytology showed that osteoblasts (OBs) exhibited higher alkaline phosphatase activity (ALP) after exposure to TMC nanoparticle material. Furthermore, TMC nanoparticles increased the uptake of water-soluble quantum dots (QDs) by OBs, and both nanoparticles and VCM/TMC mixtures improved OB proliferative activity. We also investigated the minimum inhibitory concentration (MIC, 60 µg/mL), half maximal inhibitory concentration (IC50, 48.47 µg/mL), diameter of inhibition zone (DIZ, 1.050 cm), Polymers 2015, 7 1851 and turbidimetric (TB) assay of nanoparticles. All data demonstrated that VCM/TMC nanoparticles had excellent antibacterial activity against the Gram-positive bacterium Staphylococcus aureus. These findings suggest that VCM-loaded TMC nanoparticles have good potential for the sustained delivery of antibiotics to bone infections.

show abstract

Section: Characterization Of Vcm/tmc Nanoparticlescontrasting

confidence: 50%

Preparation and Evaluation of Vancomycin-Loaded N-trimethyl Chitosan Nanoparticles

Shou³

et al. 2015

Polymers

View full text Add to dashboard Cite

show abstract

“…In addition, TMC possesses intrinsic adjuvanticity. [39][40][41] Another major challenge in oral vaccine development is oral tolerance, which downregulates cell-mediated and humoral immune responses in the gastro-intestinal tract to ensure local homeostasis. As the mucosal absorption of soluble antigens is generally very low, preferential induction of tolerance occurs in the absence of adjuvants.…”

Section: Challenges In the Development Of Oral Vaccine Formulationsmentioning

confidence: 99%

Recent advances in oral vaccine development

Smet

Allais

Cuvelier

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…For intranasal or inhalational routes, the vaccine components must be small enough to reach deep alveoli (<5 μm) and avoid clearance during exhalation (<500 nm). 6 As a result of their size, foreign composition and numerous carrying capabilities, nanoparticles have the ability to modulate various aspects of the immune response 43 and may improve the efficiency of mucosal and injected vaccines because of increased exposure time and uptake of antigens by APCs, 44 improved immunogenicity of viral and bacterial components and modulation of the cytokine response. 45 Numerous synthetic nanoparticle vaccines and immunostimulatory adjuvants have been created and include polymeric and non-polymeric based particles.…”

confidence: 99%